Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

By M. O’Donoghue, E. Braunwald, E. Antman, S. Murphy, E. Bates, Y. Rozenman, A. Michelson, R. Hautvast, Peter N. Ver Lee, S. Close and 4 more. The Lancet, 2009

763 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/fc581069c607e7b985b29f8971fb69f3856fdbe7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. J. Halperin
3. Judith Hochman
4. M. Creager
5. C. Yancy
6. M. Gheorghiade
7. Véronique L. Roger

In Endocrinology, Diabetes and Metabolism

1. M. Creager
2. Véronique L. Roger

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “Proton-pump inhibitors, most prominently omeprazole, can interfere with clopidogrel metabolism and result in diminished in vitro antiplatelet effect,(291) but it does not appear that this pharmacokinetic effect translates into worse clinical outcomes.(291,292) Prasugrel, an alternative thienopyridin”
• Guidelines on myocardial revascularization. (2010, methodology): “Post hoc analyses of CREDO and TRITON-TIMI 38 RCTs [258] did not show increased thromboembolic events.”